Amgen Inc., Eli Lilly & Co. and Teva Pharmaceutical Industries Ltd. reported new details from recently completed Phase III clinical trials for their competing CGRP inhibitors in the treatment of migraine headaches, but the endpoint used to satisfy regulators may not be the most important data point for doctors and patients.
Response Rates Rule In CGRP Inhibitor Migraine Studies
The primary endpoint in CGRP inhibitor trials is the average reduction in monthly headache days, but the scientific program committee chair for the recent American Headache Society meeting told Scrip that response rates are more important for doctors who treat migraine patients.